A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Trial Profile

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Psychotic disorders
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jan 2011 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 18 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top